[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2099064T3 - Derivados de fumagillol. - Google Patents

Derivados de fumagillol.

Info

Publication number
ES2099064T3
ES2099064T3 ES89116052T ES89116052T ES2099064T3 ES 2099064 T3 ES2099064 T3 ES 2099064T3 ES 89116052 T ES89116052 T ES 89116052T ES 89116052 T ES89116052 T ES 89116052T ES 2099064 T3 ES2099064 T3 ES 2099064T3
Authority
ES
Spain
Prior art keywords
substituted
group
optionally
carbamoyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89116052T
Other languages
English (en)
Inventor
Shoji Kishimoto
Takeshi Fujita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2099064T3 publication Critical patent/ES2099064T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/28—Ethers with hydroxy compounds containing oxirane rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

EL CONJUNTO DE FORMULA (I) DONDE R1 ES: UN GRUPO ISOBUTILICO 2-METIL-1-PROPANIL EL CUAL PUEDE SER SUBSTITUIDO Y R2 ES (1) UN GRUPO ALCANOICO, (2) UN GRUPO ARALICO SUBSTITUIDO QUE TIENE AL MENOS UN SUSTITUYENTE SELECCIONADO DE UN GRUPO QUE CONSISTE EN ALQUILICO C2-6, AMINO, HALOGENO, HIDROXILICO, ALCOXILICO REBAJADO, CIANO, CARBAMOILICO Y CARBOXILICO, (3) UN CARBONILICO-HETEROCICLICO, EL CUAL PUEDE SER OPCIONALMENTE SUSTITUIDO, (4) UN GRUPO CARBAMOLICO, QUE PUEDE SER OPCIONALMENTE SUSTITUIDO, (5) UN GRUPO ALQUILICO, QUE PUEDE SER OPCIONALMENTE SUSTITUIDO, (6) UN GRUPO BENCENESULFONILICO QUE PUEDE SER OPCIONALMENTE SUBSTITUIDO (7) UN GRUPO ALQUILOSULFONILICO, QUE PUEDE SER OPCIONALMENTE SUSTITUIDO, (8) UN GRUPO SULFAMOILICO, QUE PUEDE SER OPCIONALMENTE SUSTITUIDO (9) UN GRUPO ALCOXICARBONILICO QUE PUEDE SER OPCIONALMENTE SUBSTITUIDO O (10) UN GRUPO FENOXICARBONILICO QUE PUEDE SER OPCIONALMENTE SUSTITUIDO, O UNA SAL DEL MISMO. EL COMPUESTO (I) TIENE UNA FUERTE ACTIVIDAD INHIBIDORA DEL ANGIOGENESIS.
ES89116052T 1988-09-01 1989-08-31 Derivados de fumagillol. Expired - Lifetime ES2099064T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21928788 1988-09-01
JP5353789 1989-03-06

Publications (1)

Publication Number Publication Date
ES2099064T3 true ES2099064T3 (es) 1997-05-16

Family

ID=26394244

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89116052T Expired - Lifetime ES2099064T3 (es) 1988-09-01 1989-08-31 Derivados de fumagillol.

Country Status (7)

Country Link
US (1) US5698586A (es)
EP (2) EP0359036B1 (es)
KR (1) KR0138530B1 (es)
AT (1) ATE150750T1 (es)
DE (1) DE68927904T2 (es)
ES (1) ES2099064T3 (es)
GR (1) GR3023745T3 (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
TW282399B (es) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6903084B2 (en) 1991-08-29 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
ES2110573T3 (es) 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
DE69311278T2 (de) * 1992-12-16 1997-10-30 Takeda Chemical Industries Ltd Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
US5290887A (en) * 1993-04-30 1994-03-01 The Dow Chemical Company Epoxy resins containing thiadiazole and/or oxadiazole moieties
US5387657A (en) * 1993-09-10 1995-02-07 The Dow Chemical Company Epoxy resins containing thiadiazole and/or oxadiazole moieties
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
ATE198152T1 (de) * 1994-09-30 2001-01-15 Takeda Chemical Industries Ltd Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
US5710148A (en) * 1995-03-06 1998-01-20 Senju Pharmaceuticals Co., Ltd. Corneal opacification inhibitory composition
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
CA2208336A1 (en) * 1996-06-20 1997-12-20 Hisamitsu Pharmaceuticals Co., Inc. A device structure for iontophoresis
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
EP0970102A1 (en) 1997-03-21 2000-01-12 The President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
WO1998056372A1 (en) 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
US6482802B1 (en) 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
WO1999061432A1 (en) * 1998-05-12 1999-12-02 Biochem Pharma Inc. Fumagillin analogs and their use as angiogenesis inhibitors
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
AU6409499A (en) * 1998-10-01 2000-04-17 Children's Medical Center Corporation Method of treatment of cardiovascular injuries
JP4414517B2 (ja) 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
CA2390095C (en) 1999-11-10 2013-01-08 M. Rigdon Lentz Method and system to remove cytokine inhibitor in patients
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6919307B2 (en) 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1330447A2 (en) 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
WO2003027104A1 (en) * 2001-09-27 2003-04-03 Idrtech Inc. Fumagillol derivatives and preparing method thereof
FR2832149B1 (fr) * 2001-11-09 2006-01-06 Galderma Res & Dev Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
WO2003086382A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
EP1494699A4 (en) * 2002-04-11 2009-07-22 Childrens Medical Center METHOD FOR INHIBITING VASCULAR HYPERPERMEABILITY
AU2003299509A1 (en) * 2002-06-21 2004-05-13 University Of Utah Research Foundation Crosslinked compounds and methods of making and using thereof
CN101137388A (zh) 2003-05-15 2008-03-05 犹他卅大学研究基金会 抗粘连复合材料及其应用方法
EP1694712A1 (en) 2003-12-04 2006-08-30 University of Utah Research Foundation Modified macromolecules and methods of making and using thereof
US20100330143A1 (en) 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
CA2550873A1 (en) * 2003-12-29 2005-07-21 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
KR100552043B1 (ko) * 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
WO2006002082A2 (en) * 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
US20080248030A1 (en) * 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
CA2649915A1 (en) * 2006-04-20 2007-11-01 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US8747870B2 (en) 2006-04-20 2014-06-10 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
EP2038309A2 (en) * 2006-07-11 2009-03-25 University of Utah Research Foundation Macromolecules modified with electrophilic groups and methods of making and using thereof
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
NZ600039A (en) * 2007-11-28 2013-11-29 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
CA2731020A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
KR20110039842A (ko) * 2009-10-12 2011-04-20 주식회사 바이오씨에스 이미다졸 화합물을 유효성분으로 포함하는 안구의 혈관 신생 관련 질환의 예방 및 치료용 조성물
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
CA2806221A1 (en) 2010-07-22 2012-01-26 Zafgen, Inc. Tricyclic compounds and methods of making and using same
AU2011326566B2 (en) 2010-11-09 2016-12-01 Zafgen, Inc Crystalline solids of a MetAP-2 inhibitor and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
MX2013005989A (es) 2010-11-29 2013-08-21 Zafgen Inc Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol.
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
AU2012225531B2 (en) 2011-03-08 2017-03-30 Zafgen, Inc Oxaspiro (2.5) octane derivatives and analogs
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
EA025526B1 (ru) 2011-05-06 2017-01-30 Зафджен Инк. Частично насыщенные трициклические соединения и способы их получения и применения
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
EP2804856B1 (en) 2012-01-18 2017-03-15 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
MX2014013525A (es) 2012-05-07 2015-10-22 Zafgen Inc Sal polimorfica de la sal de oxalato de 6-o-(4-dimetilaminoetoxi)c inamoil fumagilol y metodos para elaborarla y utilizarla.
JP2015516426A (ja) 2012-05-08 2015-06-11 ザフゲン，インコーポレイテッド ＭｅｔＡＰ２阻害剤による視床下部性肥満症の治療
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
JP2016513722A (ja) 2013-03-14 2016-05-16 ザフゲン，インコーポレイテッド 腎臓病及び他の疾患の治療方法
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67646A0 (en) 1982-01-15 1983-05-15 Lilly Co Eli Ascorbic acid ethers and related compounds
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
JP2544136B2 (ja) 1986-05-23 1996-10-16 第一製薬株式会社 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
JP2806454B2 (ja) * 1988-01-19 1998-09-30 武田薬品工業株式会社 脈管形成阻止剤
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
CA1329771C (en) * 1988-09-01 1994-05-24 Shoji Kishimoto Angiogenesis inhibitory agent

Also Published As

Publication number Publication date
DE68927904T2 (de) 1997-09-04
US5698586A (en) 1997-12-16
GR3023745T3 (en) 1997-09-30
EP0359036B1 (en) 1997-03-26
ATE150750T1 (de) 1997-04-15
KR900004722A (ko) 1990-04-12
DE68927904D1 (de) 1997-04-30
EP0682020A1 (en) 1995-11-15
EP0359036A1 (en) 1990-03-21
KR0138530B1 (ko) 1998-05-15

Similar Documents

Publication Publication Date Title
ES2099064T3 (es) Derivados de fumagillol.
ATE119774T1 (de) Imidazopyridinderivate und ihre verwendung.
ES2088537T3 (es) Derivados de piranil cianoguanidina.
DK0486948T3 (da) Forbindelser, der hæmmer retrovirale proteaser
ATE126509T1 (de) Disäuren von diarylstyrylchinolin.
FI903331A0 (fi) Substituerade kinazolinoner, vilka aer anvaendbara som angiotensin-ii-antagonister.
DK0747374T3 (da) Sulfonamidsubstituerede benzopyraner som kaliumkanalaktivatorer
AU5777490A (en) Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
EP0902007A4 (en) CHALCON DERIVATIVES AND MEDICINES THAT CONTAIN THEM
ES2090048T3 (es) Derivados de xantina.
DE69022368D1 (de) Quinolin-3-carboxanilid-derivate.
NO902394D0 (no) Fremgangsmaate for fremstilling av pyranyl-cyanoguanidin-derivater.
ATE122344T1 (de) Naphthyloxazolidon-derivate.
CA2037975A1 (en) 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
DK0641770T3 (da) Hidtil ukendte forbindelser med blodpladeaggegationsinhiberende aktivitet
ES2091489T3 (es) Derivados de imidazol y composiciones farmaceuticas que los contienen.
ES2093037T3 (es) Derivados de beta-lactama y su preparacion.
AU5629590A (en) Triazine or triazole condensed system having serotonin 2-receptor antagonistic activity
AU1246092A (en) Oxoisoindoline phenyl derivatives of thiazolidine-2,4-dione
DE69213049D1 (de) Isoquinolinderivate
TH13552EX (th) อนุพันธุ์ต่าง ๆ ของเบนโซฟิโนน
TH5599A (th) อนุพันธุ์ของคาร์บาโมอิลลอกซีไธโอฟีน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 359036

Country of ref document: ES